448 related articles for article (PubMed ID: 7791096)
1. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.
Welch SP; Thomas C; Patrick GS
J Pharmacol Exp Ther; 1995 Jan; 272(1):310-21. PubMed ID: 7815346
[TBL] [Abstract][Full Text] [Related]
3. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
Welch SP
Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
[TBL] [Abstract][Full Text] [Related]
4. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
Smith PB; Compton DR; Welch SP; Razdan RK; Mechoulam R; Martin BR
J Pharmacol Exp Ther; 1994 Jul; 270(1):219-27. PubMed ID: 8035318
[TBL] [Abstract][Full Text] [Related]
6. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
7. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.
Welch SP
J Pharmacol Exp Ther; 1993 May; 265(2):633-40. PubMed ID: 8388455
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.
Welch SP; Stevens DL
J Pharmacol Exp Ther; 1992 Jul; 262(1):10-8. PubMed ID: 1320680
[TBL] [Abstract][Full Text] [Related]
9. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith PB; Welch SP; Martin BR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists: a common mechanism of action?
Welch SP; Dunlow LD
J Pharmacol Exp Ther; 1993 Oct; 267(1):390-9. PubMed ID: 8229767
[TBL] [Abstract][Full Text] [Related]
11. Antinociception and delta-1 opioid receptors in the rat spinal cord: studies with intrathecal 7-benzylidenenaltrexone.
Hammond DL; Stewart PE; Littell L
J Pharmacol Exp Ther; 1995 Sep; 274(3):1317-24. PubMed ID: 7562504
[TBL] [Abstract][Full Text] [Related]
12. Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice.
Raffa RB; Stone DJ; Hipp SJ
Neurosci Lett; 1999 Mar; 263(1):29-32. PubMed ID: 10218903
[TBL] [Abstract][Full Text] [Related]
13. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
Lichtman AH; Cook SA; Martin BR
J Pharmacol Exp Ther; 1996 Feb; 276(2):585-93. PubMed ID: 8632325
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
15. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
Pugh G; Smith PB; Dombrowski DS; Welch SP
J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
[TBL] [Abstract][Full Text] [Related]
16. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
Smith FL; Fujimori K; Lowe J; Welch SP
Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
[TBL] [Abstract][Full Text] [Related]
17. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive and morphine modulatory actions of spinal orphanin FQ.
Jhamandas KH; Sutak M; Henderson G
Can J Physiol Pharmacol; 1998 Mar; 76(3):314-24. PubMed ID: 9673795
[TBL] [Abstract][Full Text] [Related]
19. A proposed mechanism of action for the antinociceptive effect of intrathecally administered calcium in the mouse.
Welch SP; Stevens DL; Dewey WL
J Pharmacol Exp Ther; 1992 Jan; 260(1):117-27. PubMed ID: 1346158
[TBL] [Abstract][Full Text] [Related]
20. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
